Evofem Biosciences is a biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. Co. is utilizing its proprietary Multipurpose Vaginal pH Regulator (MVP-R) platform to product candidates for several potential indications, including prevention of pregnancy and prevention of certain sexually transmitted infections. Co. is developing its primary MVP-R product candidate, Phexxi, a non-hormonal, woman-controlled vaginal gel, for three potential indications: prevention of pregnancy, prevention of urogenital Chlamydia trachomatis infection and prevention of urogenital Neisseria gonorrhoeae infection. The EVFM stock yearly return is shown above.
The yearly return on the EVFM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EVFM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|